A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors (NCT06695845)
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
- Rocky Mountain Cancer Center — Littleton, Colorado
- Florida Cancer Specialists - South — Fort Myers, Florida
- Florida Cancer Specialists - Lake Nona — Orlando, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Florida Cancer Specialists - East — West Palm Beach, Florida
- Affiliated Oncologists — Chicago Ridge, Illinois
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- Alliance Cancer Specialists — Horsham, Pennsylvania
- Tennessee Cancer Specialists — Knoxville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
- Blue Ridge Cancer Care — Roanoke, Virginia
- National Cancer Center Suwon — Suwon, Gyeonggi-do
- The Catholic University of Korea St Vincent's Hospital — Suwon, Gyeonggi-do
- Chonnam National University Hwasun Hospital — Hwasun-Eup, Hwasun-Gun
- Samsung Medical Center — Gangnam-gu, Seoul
- Korea University Guro Hospital — Guro-gu, Seoul
- Seoul National University Hospital — Jongno-gu, Seoul
- Severance Hospital — Seodaemun-gu, Seoul
- The Catholic University of Korea Seoul St. Mary's Hospital — Seoul,
📞 Contact the Study Coordinator
Phone: (215) 832-3750
Email: ClinicalTrialDisclosure@JazzPharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.